Xolair, a drug developed 15 years ago by Roche and Novartis, received a breakthrough designation from the US regulator in a new food allergy indication. The Food and Drug Administration (FDA ...

New treatment options are revolutionizing ways to manage and reduce the effects of food allergy. Biologics - medications that ...

Leading pharmacy benefit managers are shifting away from lucrative rebates on biologic drugs and toward lower-cost biosimilar ...

The new-generation drug – also known as QGE031 – binds more tightly to IgE than Roche-partnered Xolair (omalizumab), and that suggests it could be more effective as a treatment for CSU ...

Dr. Daniel Jobe, the medical mirector at UNC Campus Health, said that Campus Health had over 100 student visits for allergies ...

Food allergies are on the rise. For kids with less severe peanut allergies, one potential treatment could be found in the ...

Learn more about whether Alkermes plc or Alvotech is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Alvotech or Halozyme Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Newsweek reached out to BCBS via email for comment. The policy change affects asthma patients who rely on biologic ...

Pollen season is getting longer and more intense, but these steps can keep you comfortableThe first line of defense against ...

Here’s a rundown of common medications and when it’s appropriate ... body that can worsen allergic symptoms. The biological omalizumab (Xolair) can help if you have severe seasonal allergies ...

Starting April 15, Blue Cross Blue Shield of Montana will require prior authorization for certain asthma injections in a clinic setting.